Lipid nanoparticles (LNPs) are the leading non-viral platform for mRNA delivery. Their core–shell architecture encapsulates mRNA and shields it from nuclease degradation and premature leakage in circulation, while the particle surface can be engineered to direct uptake to specific cell types.
Building on this surface tunability, targeted LNPs (tLNPs) display ligands — antibody fragments including single-domain VHHs, peptides, or aptamers — that redirect particles away from the default ApoE/LDLR-driven hepatocyte uptake and toward a chosen cell type, reducing off-target exposure and the dose required for effect.
This makes tLNPs a practical route to in vivo CAR-T therapy. T-cell-targeted tLNPs deliver CAR mRNA directly to T cells in the patient, giving transient, T cell–selective CAR expression without ex vivo manufacture or lymphodepletion. Because the payload is mRNA, there is no genomic integration and therefore no insertional mutagenesis risk; because expression is transient, dosing can be repeated and the CAR construct updated by changing the mRNA payload — provided formulation and CMC are re-qualified for each construct.



Pharmacopoeia-Grade Encapsulation Efficiency detection— Without Triton X-100

—Fluorescence labeling meets single-molecule detection—quantifying surface ligand density and protein copy number on mRNA-LNPs.
